Is Editas Medicine, Inc. (EDIT) a Buy, Sell, or Hold?
Editas Medicine, Inc.
NASDAQ:EDIT
$3.16 USD
$0 (0.0%)
- Volume
- 1.84M
- Average Volume
- 2.52M
- Market Capitalization
- $309.36M
- P/E Ratio
- -2.57
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $4.54
- Year Low
- $1.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.22
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gilmore O'Neill |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EDIT |
| CUSIP | 28106W103 |
| CIK | 0001650664 |
| Web | https://www.editasmedicine.com |
| Phone | 617 401 9000 |
| Currency | USD |
| Employees | 87 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 16.33 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.22 |
| Quick Ratio | 3.22 |
| Cash Ratio | 3.11 |
Sales & Book Value
| Annual Sales | $40.52M |
| Price / Sales | 8.00 |
| Cash Flow | -1.44 |
| Price / Cash Flow | -2.19 |
| Price / Book | 70.17 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -36.80% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.8 |
| Trailing P/E Ratio | -2.57 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-160.06M |
| Net Margin | -281.59% |
| Pretax Margin | -281.59% |
| Return on Equity | -677.39% |
| Return on Assets | -72.96% |
Financials Score
| AltmanZ Score | -15.55 |
| Piotroski Score | 3.00 |
| Working Capital | 88.29M |
| Total Assets | 149.34M |
| Ebit | -103.93M |
| Market Cap | 309.36M |
| Total Liabilities | 144.93M |
Poll Results
About Editas Medicine, Inc. (NASDAQ:EDIT) Stock
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Geng ... ine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
2026-06-17 12:30:08
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
2026-05-31 12:11:48
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
2026-05-28 16:01:00
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
2026-05-26 09:05:00
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.
Editas Medicine Announces Proposed Public Offering
2026-05-26 06:15:03
CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof).
Editas Medicine Announces Proposed Public Offering
2026-05-26 06:15:00
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be sold by Editas Medicine.
2026-05-26 06:01:00
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026 CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece on May 25, 2026.
2026-05-14 06:01:00
CAMBRIDGE, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued advancement of Editas' lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the broader potential of the Company's differentiated upregulation strategy.
Frequently Asked Questions
-
What is the current Editas Medicine, Inc. (EDIT) stock price?
-
Editas Medicine, Inc.(NASDAQ:EDIT) stock price is $3.16 in the last trading session. During the trading session, EDIT stock reached the peak price of $4.537 while $1.66 was the lowest point it dropped to. The percentage change in EDIT stock occurred in the recent session was 0.0% while the dollar amount for the price change in EDIT stock was $0.
-
EDIT's industry and sector of operation?
-
The NASDAQ listed EDIT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EDIT?
-
Brieana Buckley | Senior Vice President of Development and Program Leadership
Feng Zhang | Co-Founder & Scientific Advisory Board Member
George McDonald Church | Co-Founder & Scientific Advisory Board Member
Frank Panaccio | Senior Vice President & Chief Business Officer
Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary -
How many employees does EDIT have?
-
Number of EDIT employees currently stands at 87. EDIT operates from 11 Hurley Street, Cambridge, MA 02141, US.
-
Link for EDIT official website?
-
Official Website of EDIT is: https://www.editasmedicine.com
-
How do I contact EDIT?
-
EDIT could be contacted at phone #617 401 9000 and can also be accessed through its website. EDIT operates from 11 Hurley Street, Cambridge, MA 02141, US.
-
How many shares of EDIT are traded daily?
-
The average number of EDIT shares traded daily for last 3 months was 2.52M.
-
What is the market cap of EDIT currently?
-
The market value of EDIT currently stands at $309.36M with its latest stock price at $3.16